Rohto Pharmaceutical Co.,Ltd.
Other OTCTotal Valuation
Rohto Pharmaceutical Co.,Ltd. carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 690.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.39B |
| Enterprise Value | 690.44B |
Share Statistics
Rohto Pharmaceutical Co.,Ltd. currently has 228.14M shares outstanding.
| Shares Outstanding | 228.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Rohto Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 48.75. The price-to-sales ratio is 4.89, and the price-to-book ratio stands at 3.17.
| PE Ratio | 48.75 |
| PS Ratio | 4.89 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.39 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Rohto Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 36.18 and an EV/FCF ratio of 10,334.92. The EV/Sales ratio of 4.83 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.18 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.83 |
| EV / EBITDA | 36.18 |
| EV / EBIT | 36.18 |
| EV / FCF | 10,334.92 |
Financial Position
Rohto Pharmaceutical Co.,Ltd. maintains a current ratio of 1.84, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.85, indicating elevated leverage, while an interest coverage ratio of 219.37 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.84 |
| Quick Ratio | 0.58 |
| Debt / Equity | 16.85 |
| Debt / EBITDA | 2.33 |
| Interest Coverage | 219.37 |
Financial Efficiency
Rohto Pharmaceutical Co.,Ltd. posts a return on equity of 6.75 and a return on invested capital of 5.15.
| Return on Equity (ROE) | 6.75 |
| Return on Assets (ROA) | 3.86 |
| Return on Invested Capital (ROIC) | 5.15 |
| Return on Capital Employed (ROCE) | 5.71 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.08 |
Taxes
Over the trailing twelve months, Rohto Pharmaceutical Co.,Ltd. has paid 4.40B in income taxes, reflecting an effective tax rate of 23.21.
| Income Tax | 4.40B |
| Effective Tax Rate | 23.21 |
Stock Price Statistics
Rohto Pharmaceutical Co.,Ltd.'s stock has declined approximately -25.33599% over the past 52 weeks. The 50-day moving average sits at 15.14, while the 200-day moving average is 15.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.33599% |
| 50-Day Moving Average | 15.14 |
| 200-Day Moving Average | 15.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Rohto Pharmaceutical Co.,Ltd. generated 142.97B in revenue and converted that into 14.34B in net income, yielding earnings per share of 63.69. EBITDA reached 19.09B, while operating income came in at 19.09B.
| Revenue | 142.97B |
| Gross Profit | 83.33B |
| Operating Income | 19.09B |
| Pretax Income | 18.97B |
| Net Income | 14.34B |
| EBITDA | 19.09B |
| EBIT | 19.09B |
| Earnings Per Share (EPS) | 63.69 |
Balance Sheet
Rohto Pharmaceutical Co.,Ltd. holds 64.50B in cash and equivalents against 44.54B in total debt, resulting in a net debt position of -19.97B. Total book value stands at 220.85B, with working capital of 93.75B providing operational flexibility.
| Cash & Cash Equivalents | 64.50B |
| Total Debt | 44.54B |
| Net Debt | -19.97B |
| Equity (Book Value) | 220.85B |
| Book Value Per Share | 968.06 |
| Working Capital | 93.75B |
Margins
Rohto Pharmaceutical Co.,Ltd. operates with a gross margin of 58.28, reflecting its pricing power and cost economics. The operating margin of 13.35 and net profit margin of 10.03 provide insight into operational efficiency.
| Gross Margin | 58.28 |
| Operating Margin | 13.35 |
| Pretax Margin | 13.27 |
| Profit Margin | 10.03 |
| EBITDA Margin | 13.35 |
Stock Splits
Rohto Pharmaceutical Co.,Ltd.'s most recent stock split took place on December 29, 2022 with a 1:2 split ratio.
| Last Split Date | 12/29/2022 |
| Split Ratio | 1:2 |
Scores
Rohto Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 4.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.68 |